Home

The content presented here was prepared by independent authors under the editorial supervision of Creative Educational Concepts, Inc. and does not represent a publication of the American Society of Clinical Oncology. These materials are not sanctioned by ASCO and do not constitute an official part of that meeting.

Target Audience
This activity has been designed to meet the educational needs of oncologists and physicians who are involved in the care and treatment of patients with GIST.

Statement of Need
Cancer is the second leading cause of death in the United States, and places a significant burden on the healthcare community. In an attempt to prevent cancer-related deaths, the armamentarium of available treatment options continues to expand, particularly in the area of pharmacologic treatment. It is essential that the healthcare community remains up to date with the latest data on advancements in pharmacotherapy. The results of multiple and varied cancer research studies are presented each year at the American Society of Clinical Oncology (ASCO) annual meeting. This activity will enable participants to receive information that was presented at the much larger society meeting, in a smaller forum. Patterns of practice have the potential to change based on new data, and the accessibility to this overview allows participants to remain informed.

Educational Objectives
Upon completion of this activity, participants should be better able to:

• Consider the clinical impact of emerging therapies for GIST.
• Evaluate the published data based on study design, the reported results, and authors’ conclusions.
• Consider the reviewed data as it relates to previous, current and future treatment of GIST.
• Consider treatment options for GIST patients who have developed primary or secondary resistance to current treatment.

Faculty Information

Douglas S. Tyler, MD Professor of Surgery Duke University Medical Center Durham, North Carolina

Biography

Douglas Tyler, MD is currently a Professor of Surgery at Duke University Medical Center. Dr. Tyler completed his undergraduate education in 1981 at Dartmouth College and received his Medical Degree in 1985 from Dartmouth Medical School. Upon completion of his training he spent 2 years at MD Anderson Cancer Center in their Surgical Oncology Fellowship before being recruited back to Duke in 1994.

Dr. Tyler’s clinical practice focuses on GI cancers and melanoma. He performs over 500 cases per year. Since 1997, he has been a member of the Duke Comprehensive Cancer Center. Dr. Tyler has published over 120 peer reviewed manuscripts and runs a funded research laboratory that focuses on novel strategies to overcome tumor chemoresistance as it pertains to regional melanoma therapy. Dr. Tyler also runs the largest regional chemotherapy treatment and clinical research program in the country. He is currently the PI on several phase I regional therapy trials in melanoma.

Nationally, Dr. Tyler is currently on the Executive Committee of the Society of Surgical Oncology and a member of numerous other societies including the American Surgical Association and the Society of Clinical Surgery. Dr. Tyler is also active teaching both residents and medical students for which he has won the David C. Sabiston Teaching award twice (1998 and 2007) and the Davison Medical Student Teaching award once (1999).

Disclosures

Faculty: Dr. Tyler has no financial relationships to disclose relating to the content of this activity.

Contributing Editor: Jennifer Maxon, RN has no financial relationships to disclose relating to the content of this activity.

Planners: The planners and managers have no financial or other relationships to products or devices with commercial interests related to the content of this CME activity

Instructions
To receive a statement of credit, you must:

• Review the full content of the activity and reflect upon its teachings
• Complete the questions and evaluation at the end of the activity

Accreditation

Medicine

Creative Educational Concepts, Inc. (CEC) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. CEC designates this educational activity for a maximum of .50 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Fee
This activity is complimentary.

Disclosure Declaration
It is the policy of CEC ensure independence, balance, objectivity, scientific rigor, and integrity in their continuing education activities. Those involved in the development of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education activity. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, and precautions) and drug delivery systems is subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems. Fair balance is achieved through ongoing and thorough review of all presentation materials produced by faculty, and all educational and advertising materials produced by supporting organizations, prior to educational offerings. Approval of credit for this continuing education activity does not imply endorsement by CEC of any product or manufacturer identified.

Unlabeled Use Disclosure
This activity may include discussions of products or devices that are not currently approved for use by the Food and Drug Administration (FDA), or are currently investigational.

Supporting Organization
This activity is supported by an educational grant from Novartis Oncology.

Viewing Requirements
This Website requires version 4.x browsers or higher from Microsoft or Netscape. It has been optimized for Microsoft Browsers.